Individualizing treatment choices for patients with type 2 diabetes according to patient preference

Many patients with Type 2 diabetes will require additional glucose lowering treatment to achieve optimal control. Ensuring adherence is therefore crucial in order reduce the long-term risks of complications. A study recently published Nature Medicine, known as TriMaster first evaluate effectiveness allowing people type choose their own second/third line medication manage hyperglycaemia. This approach was thought balance potential efficacy side effects profiles selected drugs. The led by academics from University Exeter a randomized double-blind, three-way cross over trial where received three different second- or third-line once-daily glucose-lowering drugs (pioglitazone 30 mg, sitagliptin 100 mg and canagliflozin mg). As part prespecified secondary endpoint, patients' drug preference were examined after they had tried all In total, 448 participants treated which overall showed similar outcomes. terms preference, 115 (25%) preferred pioglitazone, 158 (35%) 175 (38%) canagliflozin. individual associated lower HbA1c (mean: 4.6; 95% CI: 3.9, 5.3) mmol mol−1 versus nonpreferred) fewer 0.50; 0.35, 0.64) nonpreferred). that allocating therapy based on individually drugs, rather than most (canagliflozin), would result more achieving lowest for them (70% 30%) fewest (67% 50%). Given comparable ability try suitable medications before according could be practical alternative individualised strategy facilitate compliance.